Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States

Abstract

The cost effectiveness of adding NAT screening is outside the typical range for most healthcare interventions, but not for established blood safety measures.